Peptide Nasal Sprays: How Research Sprays Are Formulated and Stored

A research peptide nasal spray is a solution of known concentration in a metered-pump bottle, and its defining specification is not the peptide mass on the label but the mass delivered per actuation — concentration multiplied by the pump's fixed spray volume. Peptide nasal sprays exist in research because the nasal mucosa is thin, richly vascularised and directly adjacent to olfactory and trigeminal pathways, which makes it the standard non-parenteral route in intranasal delivery studies. This guide covers how these formulations are built, what limits which peptides can be sprayed, how to calculate per-actuation mass, and how liquid sprays behave in storage compared with lyophilized vials. All of it describes laboratory reference preparations.

Why intranasal is studied at all

Peptides taken orally are degraded by gastric acid and by pancreatic and brush-border peptidases, and what survives faces hepatic first-pass metabolism; measured oral bioavailability for unmodified peptides is typically well under 1%, which is the problem discussed in oral peptides, capsules and troches. The nasal cavity offers roughly 150 cm² of thin, highly perfused epithelium with far less proteolytic activity and no portal drainage. Published intranasal work with small peptides has reported bioavailability figures ranging from a few percent to the low tens of percent depending on molecule and formulation — an enormous improvement over oral, still far below injection.

The second reason is anatomical. Rodent and non-human primate studies since the 1990s have reported that molecules deposited on the olfactory epithelium can reach cerebrospinal fluid and brain tissue along perineural spaces of the olfactory and trigeminal nerves, apparently bypassing the blood–brain barrier. That literature is why nootropic sequences dominate our nasal peptide sprays range — Semax, Selank and similar molecules are exactly the ones where a direct nose-to-brain route is the research question. The mechanism remains debated and the human evidence is thin; describe it as reported, not established.

What limits which peptides can be sprayed

• Molecular weight. Nasal absorption falls steeply above roughly 1,000 Da. Semax (813.93 Da) and Selank (751.89 Da) sit under that ceiling; a 4,113 Da GLP-1 analogue does not, which is why the sprayed formats in the catalogue skew small.
• Volume. The nasal cavity retains only about 100–150 µL before excess runs off, so a metered pump is built around a 0.1 mL actuation. Concentration, not volume, is the only lever for increasing delivered mass.
• Mucociliary clearance. Deposited material is swept toward the nasopharynx within roughly 15–20 minutes, capping residence time regardless of formulation.
• Chemical stability in water. A spray is an aqueous solution held at room temperature for weeks. Sequences containing methionine, cysteine or Asn-Gly motifs are the ones most likely to show oxidation, disulfide scrambling or deamidation over that window.

What is in a peptide nasal spray bottle

Permeation enhancers — chitosan, cyclodextrins, bile-salt derivatives — appear throughout the intranasal literature and can raise measured absorption several-fold, but they also raise epithelial irritation in tissue models, so they belong in a formulation study rather than in a general-purpose research spray.

Worked example: from vial to per-actuation mass

Our nasal spray reconstitution kit supplies an empty 15 mL metered bottle plus buffered diluent, so the arithmetic is yours to set.

1. Choose the concentration. A 10 mg peptide vial transferred into 10 mL of diluent gives 10 ÷ 10 = 1 mg/mL, i.e. 1,000 mcg/mL.
2. Apply the pump volume. At 0.1 mL per actuation, each spray delivers 0.1 × 1,000 = 100 mcg.
3. Count the actuations. 10 mL ÷ 0.1 mL = 100 theoretical actuations, less 3–5 lost to priming and 0.5–1 mL of unrecoverable residue below the dip tube. Plan on roughly 85–90 usable actuations, not 100.
4. Change one variable. The same 10 mg vial in 5 mL gives 2 mg/mL and 200 mcg per actuation, with about 42 usable actuations. Halving the volume doubles delivered mass and halves the shelf life of the bottle in use.

The same mg/mL arithmetic used for injectable stocks applies here; the reconstitution calculator will run it if you enter the bottle volume in place of a vial diluent volume. If you would rather not assemble the components, the nasal spray DIY kit pairs a 10 mg Semax vial with the bottle and solution.

Verifying the pump rather than trusting it

Metered pumps are specified at 0.1 mL but individual units drift, and a pump that has not been primed delivers air or a partial volume for its first several strokes. The lab check is gravimetric: prime five times, then actuate ten times into a tared weighing boat and divide. Aqueous solutions are close enough to 1 g/mL that 1.0 g over ten actuations confirms 0.1 mL per stroke. Repeat when the bottle is roughly two-thirds empty, because delivered volume falls once the dip tube starts drawing air.

Storage and stability of the liquid format

A lyophilized vial is a dry solid and, kept frozen and dark, is stable for years. A spray is the opposite: an aqueous solution at room temperature with a septum-free opening. Every degradation route that matters for peptides — hydrolysis, deamidation, methionine oxidation, disulfide exchange, adsorption to the container wall — runs faster in solution.

• Store sealed, unopened sprays refrigerated at 2–8 °C and bring to room temperature before actuating; cold solution changes viscosity and the delivered volume with it.
• Once in use, refrigerated storage is still preferred. Preserved formulations tolerate room temperature but the peptide, not the preservative, is the limiting factor.
• Do not freeze an assembled spray. Ice formation concentrates solutes at the freeze front and can crack the pump body; freeze–thaw damage to peptide solutions is covered in how to store peptides.
• Keep bottles upright and out of light. Amber or opaque containers exist because tryptophan and tyrosine residues are photolabile.
• Treat an in-use bottle as having a working life of weeks, not months, and label it with the date it was made up. Vial labels and log sheets make that record part of the workflow rather than an afterthought.

Common mistakes

• Quoting the label mass as the delivered mass. A 10 mg bottle does not deliver 10 mg per actuation; it delivers concentration × 0.1 mL.
• Ignoring priming loss when calculating how many actuations a bottle provides.
• Reconstituting a spray with plain bacteriostatic water. It is sterile and preserved but unbuffered and hypotonic, so pH and tonicity are uncontrolled; buffered nasal diluent exists for that reason.
• Assuming a sprayable format for a large peptide. Above roughly 1,000 Da, absorption in published models drops far enough that a spray becomes a delivery study rather than a delivery method.

Further questions on formats, shelf life and shipping are collected in the nasal spray FAQ.

What the nasal range looks like against the 1,000 Da ceiling

There are seventeen nasal-spray listings in the catalogue, and sorting them by the molecular weight of their active divides them into three groups with quite different standing against the absorption ceiling described above. Ten sit comfortably below it: melatonin at 232.28 g/mol, glutathione at 307.32, Epitalon at 390.35, Pinealon at 418.41, Dihexa at 439.55, NAD+ at 663.43, Selank at 751.89, Semax at 813.93, DSIP at 848.81, and TB-500 at 889.02 in the combination spray. For these the nasal route is a delivery method with published support behind the molecular size.

Three sit almost exactly on the line: oxytocin at 1,007.19 g/mol, P-21 at 1,017.24 and PT-141 at 1,025.16. Oxytocin is the interesting case of the three, because intranasal oxytocin is one of the most heavily studied intranasal peptides in the literature despite that mass, which is a reminder that the ceiling is a steep gradient rather than a cliff and that formulation moves the number.

Three sit well above it: kisspeptin-10 at 1,302.47 g/mol, BPC-157 at 1,419.55 and Thymosin Alpha-1 at 3,108.30. For those three, a spray is a delivery study rather than a delivery method, exactly as set out under common mistakes above. That is not an argument against the format — intranasal permeation of larger peptides is a legitimate research question, and a pre-mixed metered bottle is a reasonable article to ask it with — but a protocol should say which of the two it is doing, because the expected systemic recovery differs by orders of magnitude between the first group and the third.

Concentration spans thirty-fold across an identical pump

Because the pump volume is fixed, delivered mass per actuation tracks concentration and nothing else, and the concentrations across this range are not remotely comparable. The Semax nasal spray and the Selank nasal spray are filled at approximately 0.67 mg/mL in the 10 mg bottle and 1.33 mg/mL in the 20 mg bottle, so an actuation delivers about 67 or 133 micrograms. The oxytocin nasal spray, the PT-141 nasal spray and the Kisspeptin-10 nasal spray are filled to the same 10 or 20 mg in 15 mL and therefore deliver the same 67 or 133 micrograms per stroke. The combined Semax + Selank nasal spray halves each component to roughly 0.33 or 0.67 mg/mL, giving 33 or 67 micrograms of each.

The NAD+ nasal spray is the outlier by a wide margin: 300 mg or 600 mg in 15 mL is 20 or 40 mg/mL, which at 0.1 mL per actuation is 2 or 4 milligrams per stroke — thirty times the Semax figure through an identical pump. NAD+ is not a peptide, it is a 663.43 g/mol dinucleotide, and its solutions are acidic and hydrolyse at alkaline pH, so buffer choice matters more for that bottle than for any other in the range. Whenever two sprays are being compared, convert both to mass per actuation first; the bottle labels state total content and are not comparable figures.

Two sprays that are not aqueous solutions

The Dihexa nasal spray and the P-21 nasal spray both use a co-solvent vehicle, because neither compound is freely water-soluble: Dihexa carries hexanoyl and aminohexanoyl groups at its termini and P-21 carries an adamantylated glycine. That changes the experiment in two ways worth planning for. Measured permeation in a tissue or explant model is vehicle-dependent, so a co-solvent spray cannot be compared with an aqueous one without a vehicle-only arm. And organic co-solvents affect ciliary function in explant preparations, so any tolerability readout on those two formulations is measuring the vehicle as much as the compound. A vial-versus-spray comparison on either molecule is therefore a route-and-vehicle comparison, not a route comparison.

Pre-mixed means the concentration is not yours

Every spray in the range ships pre-mixed and ready to dispense, with no reconstitution step. That removes the handling error discussed above and replaces it with a constraint: the concentration was set by the filler, so a spray cannot support a concentration–response design. A lyophilized vial plus the nasal spray reconstitution kit is the only format that can. Several listings — the BPC-157 nasal spray, the BPC-157 + TB-500 nasal spray, the Pinealon nasal spray and the Thymosin Alpha-1 nasal spray — also carry an explicit fill note stating that the 15 mL and 30 mL sizes come from the same bulk solution at the same nominal concentration. The larger bottle therefore gives roughly twice the actuations, not twice the mass per actuation, which is the opposite of what a doubled label figure suggests at a glance. The full range sits in the nasal peptide sprays collection.

Frequently Asked Questions

Related Guides

Peptide Reconstitution Math Explained: mg, mL, mcg and Insulin-Syringe Units

The three formulas every peptide reconstitution calculator runs on — concentration, volume-for-amount and the units conversion — worked through with real numbers so you can check any result by hand.

Peptide Solubility: Charge, pH, Hydrophobic Sequences and Solvent Choice

A peptide is least soluble where its net charge is zero. Count the charged residues, find which side of neutral the sequence sits on, and the solvent choice follows.

Peptide Stability and Half-Life: Why DAC, PEG and Acetylation Exist

Vial stability and biological half-life are different problems with different solutions. Here is which enzyme each modification blocks, and what the reported half-lives actually are.